GILEAD SCIENCES, INC. Deferred Tax Assets, Operating Loss Carryforwards
GILEAD SCIENCES, INC. (GILD) had Deferred Tax Assets, Operating Loss Carryforwards of $266.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $266.00M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $288.00M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $417.00M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $430.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $266.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $288.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $417.00M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $430.00M 10-K · filed 2024-02-23 | |
| 2021-12-31 | $413.00M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $587.00M 10-K · filed 2022-02-23 | |
| 2019-12-31 | $184.00M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $344.00M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $322.00M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $175.00M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $199.00M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $215.00M 10-K · filed 2016-02-24 | |
| 2013-12-31 | $228.00M 10-K · filed 2015-02-25 | $227.50M 10-K · filed 2014-02-25 |
| 2012-12-31 | $225.65M 10-K · filed 2014-02-25 | |
| 2011-12-31 | $260.91M 10-K · filed 2013-02-27 | |
| 2010-12-31 | $308.85M 10-K · filed 2012-02-23 | |
| 2009-12-31 | $377.06M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |